A Nature Biotechnology report described extensive restoration of forelimb function in rhesus monkeys after transplanting human embryonic stem cell‑derived spinal cord neural stem cells (H9‑scNSCs). The study reported functional hand recovery in a significant fraction of treated animals, marking a key preclinical advance toward clinical translation for spinal cord injury therapies. Researchers mapped synaptic integration, axon growth and functional endpoints across the cohort and reported improvement in skilled forelimb tasks compared with controls. The work included safety and dosing assessments relevant to human trial design. The result advances confidence in cell‑based regenerative approaches for spinal cord injury and moves the field closer to first‑in‑human studies; developers, CDMOs and regulators will monitor the methodology, reproducibility, and safety signals as programs consider clinical translation.